We’re pleased to introduce you to newest member of the PDCI team, Piraveena Sabesan, in her role as Associate, HTA and Health Economics!

Piraveena holds a Master of Biotechnology (Biopharmaceuticals) from the University of Toronto, and has spent the last two years working in Health Economics & Market Access at Amaris. During her time at Amaris, Piraveena was involved with the development of submissions to Canadian HTA and payers, as well as, US and European agencies.  She also has experience with advisory boards, systematic reviews, and early parallel scientific advice.  Piraveena’s primary responsibility will be to support the Health Economic team with HE and BIA model builds, adaptations, and reports.

The PDCI Health Economics team has extensive capabilities to support manufacturer HTA submissions in Canada. We have experience in pharmacoeconomic model builds, model adaptations, and budget impact models for CDR, pCODR, INESSS and private payer submissions, Additionally, we have experience in a wide range of therapeutic areas, including, but not limited to: oncology, rare disease, and immunology. Please contact Donna Lawrence, our director of HTA and Health Economics to find out how PDCI can support your upcoming submission needs and analyses.

Piraveena can be reached by email at piraveena.sabesan@pdci.ca.

Please join us in welcoming Piraveena to the PDCI team!